The granted patent is broad in scope and covers both the formulation currently being used in the international clinical study STEP as well as future generations of products containing TCP-25.
TCP-25 is already protected by patents in Europe and the United States and has also been granted Orphan Drug Designation in the United States.
“A strong intellectual property position is essential for us, and this new patent provides broad protection in a strategically important market,” says Helene Hartman, CEO of Xinnate AB.
